Welcome to This Week in Dermatology. This week we're covering 10 notable papers spanning the comparative safety and durability of biologics in inflammatory skin disease, the real-world performance of our immunomodulatory workhorses in severe and rare conditions, and a group of studies on comorbidity screening and risk stratification. Let's dive in.

This week's papers:

1. Risks of tuberculosis, meningitis, candidiasis, and fungal infections among patients receiving systemic treatments for psoriasis: a nationwide cohort study from BADBIR data. — British Journal of Dermatology 2026
2. Real-World Treatment Response to Adalimumab and Secukinumab in Chinese Adults with Hidradenitis Suppurativa: A Retrospective Cohort Study. — Dermatology 2026
3. Long-Term Effectiveness, Safety, and Survival of Dupilumab in Pediatric Atopic Dermatitis. — JAMA Dermatology 2026
4. Short-term prognostic factors of rituximab combined with glucocorticoids in the treatment of pemphigus: A multicenter retrospective study. — Journal of the American Academy of Dermatology 2026
5. Adverse Events and Real-World Outcomes of Intravenous Immunoglobulin in Dermatologic Diseases: A 20-Year Cohort Study. — Clinical and Experimental Dermatology 2026
6. Updosed Omalizumab in Chronic Spontaneous Urticaria With or Without Symptomatic Dermographism. — Clinical and Experimental Dermatology 2026
7. Treatment strategies for interstitial granulomatous dermatitis: Systematic review and expert opinion. — Journal of the European Academy of Dermatology and Venereology 2026
8. Adverse pregnancy outcomes in women with atopic dermatitis: A systematic review and meta-analysis. — Journal of the European Academy of Dermatology and Venereology 2026
9. Systematic Review and Meta-Analysis of Thyroid Disease in Children With Vitiligo. — Pediatric Dermatology 2026
10. Precision Medicine for Somatic Mutation-Driven Vascular Anomalies. — British Journal of Dermatology 2026

Listen at AudioScholar

Welcome to This Week in Dermatology. This week we're covering 10 notable papers spanning immune-targeted therapy — where one major trial failed and several others refine how we use the drugs we already have — plus skin cancer surgery and systemic comorbidity, and a final group on infection, prevention and how care gets delivered. Let's dive in.

This week's papers:

1. Efficacy and safety of subcutaneous efgartigimod with prednisone in moderate-to-severe pemphigus (ADDRESS): a global, phase III, randomised controlled, double-blind trial. — British Journal of Dermatology 2026
2. Dose optimization of deuruxolitinib in adults with alopecia areata: A phase 2 randomized trial. — Journal of the American Academy of Dermatology 2026
3. Pediatric Alopecia Areata and JAK Inhibitors: Bridging the Gap Between Evidence and Practice. — Journal of the American Academy of Dermatology 2026
4. Drug Survival of Omalizumab and Factors Associated With Discontinuation in Chronic Urticaria: A Meta-Analysis. — JAMA Dermatology 2026
5. Inflammatory Bowel Disease and Interleukin-17 Inhibitors in Hidradenitis Suppurativa: A Systematic Review and Meta-Analysis. — JAMA Dermatology 2026
6. Five-year Recurrence Rate of Cutaneous Squamous Cell Carcinoma After Mohs Micrographic Surgery Versus Standard Excision: a Prospective Multicentre Cohort Study. — British Journal of Dermatology 2026
7. Blood proteomics links systemic inflammation with early atherosclerosis in moderate-to-severe atopic dermatitis. — Journal of Investigative Dermatology 2026
8. Advances in the diagnosis and management of skin and soft tissue infections. — BMJ 2026
9. Comparison of sunscreen products for babies and children with those for adults. — Dermatology 2026
10. Veterans' Willingness to Use Home-based Telehealth and AI for Dermatology. — Journal of Investigative Dermatology 2026

Listen at AudioScholar

Welcome to This Week in Dermatology. This week we're covering 10 notable papers spanning inflammatory disease therapeutics — from a new interleukin-36 antibody in pustular psoriasis to long-term JAK inhibition in eczema — plus consensus and guideline documents that tell you what to do when standard care fails, and a cluster of cutaneous oncology papers on melanoma, transplant skin cancer, and rare…

This week's papers:

1. Efficacy and Safety of Recibokibart, an Interleukin-36 Receptor Antibody, in Generalized Pustular Psoriasis: A Phase 2 Randomized Trial. — British Journal of Dermatology 2026
2. 52-week ivarmacitinib in moderate-to-severe atopic dermatitis: A phase 3 trial. — Journal of the European Academy of Dermatology and Venereology 2026
3. RANDOMIZED CONTROLLED STUDY OF NEMOLIZUMAB IN PATIENTS WITH CHRONIC KIDNEY DISEASE AND ASSOCIATED PRURITUS: NIKAIA-1. — Journal of the American Academy of Dermatology 2026
4. Delphi Consensus Statement on Treatment of Severe Alopecia Areata in US Adults. — JAMA Dermatology 2026
5. Guidelines for diagnostic testing in adults with presumed atopic dermatitis refractory to treatment. — Journal of the American Academy of Dermatology 2026
6. Five-year survival impact of adjuvant anti-PD-1 therapy in a nationwide cohort of stage III melanoma. — Journal of the European Academy of Dermatology and Venereology 2026
7. Comparison of Pleomorphic Dermal Sarcoma to Advanced Cutaneous Squamous Cell Carcinoma and Soft-Tissue Sarcoma. — JAMA Dermatology 2026
8. HPV-Associated Cutaneous Malignancies in Solid Organ Transplant Recipients: Identification and the Role of the Dermatologist: Part 1. — Journal of the American Academy of Dermatology 2026
9. HPV-Associated Cutaneous Malignancy in Solid Organ Transplant Recipients: The Role of the Dermatologist in Management and Prevention: Part II. — Journal of the American Academy of Dermatology 2026
10. Clinicopathologic Characteristics, Treatment Outcomes of Pediatric Mycosis Fungoides in Turkey: A National Multicenter Retrospective Cohort. — Pediatric Dermatology 2026

Listen at AudioScholar

Welcome to This Week in Dermatology. This week we're covering 10 notable papers spanning systemic drug safety and the cardiometabolic interface, new targeted therapy data in inflammatory and neutrophilic skin disease, risk stratification in skin cancer, and a pair of papers that together make a strong case for looking below the neck in acne. Let's dive in.

This week's papers:

1. Cardiometabolic Associations of Dermatological Treatments. Part I: Systemic Therapies. — Journal of the American Academy of Dermatology 2026
2. Cardiometabolic Associations of Dermatological Treatments. Part II: Targeted and Biologic Therapies. — Journal of the American Academy of Dermatology 2026
3. Skin-Specific Outcomes of Brepocitinib in Patients With Dermatomyositis: Secondary Analysis of a Phase 3 Randomized Clinical Trial. — JAMA Dermatology 2026
4. A Delphi Consensus on Tildrakizumab Dosing and Titration in Moderate-to-Severe Plaque Psoriasis. — Acta Dermato-Venereologica 2026
5. Validation of the integrated 40-gene expression profile (i40-GEP) which provides prognostic and adjuvant radiation benefit for high-risk cutaneous squamous cell carcinoma. — Journal of the American Academy of Dermatology 2026
6. Comorbidity-Guided Management of Pyoderma Gangrenosum: A Clinical Guide to Emerging Therapeutic Targets. — Journal of the American Academy of Dermatology 2026
7. Global Disparities in Access to Dermatological Care. — JAMA Dermatology 2026
8. Laser and Energy-Based Device Use in Skin of Color: A Clinical Review of Safety, Efficacy, and Best Practices. — Journal of the American Academy of Dermatology 2026
9. Truncal Acne Is Independently Associated with Stigmatization, Poorer Treatment Adherence and Greater Healthcare Utilization: A 20-country Survey. — Acta Dermato-Venereologica 2026
10. Effectiveness, safety and tolerability of Ozenoxacin 2% lotion vs Clindamycin 1% lotion in mild to moderate truncal acne: An open label randomized controlled clinical trial. — Clinical and Experimental Dermatology 2026

Listen at AudioScholar

Welcome to This Week in Dermatology. This week we're covering 10 notable papers spanning inflammatory skin disease and its systemic burden, new mechanisms and management frameworks in atopic dermatitis and alopecia areata, and diagnostics for the conditions we most often miss — subclinical basal cell carcinoma, VEXAS syndrome, and male genital lichen sclerosus. Let's dive in.

This week's papers:

1. Rezpegaldesleukin treatment of moderate-to-severe atopic dermatitis (REZOLVE-AD): final results from the 16-week induction period of an international, double-blind, placebo-controlled, randomised phase 2b study. — The Lancet 2026
2. European S2k guidelines for hidradenitis suppurativa/acne inversa Part 1. Epidemiology, diagnosis and clinical assessment. — Journal of the European Academy of Dermatology and Venereology 2026
3. Alopecia areata: Emerging therapies and up-to-date management strategies. — Journal of the American Academy of Dermatology 2026
4. VEXAS Syndrome: A Comprehensive Review for Dermatologists Part 1: Epidemiology, Pathophysiology, and Clinical Presentations. — Journal of the American Academy of Dermatology 2026
5. VEXAS Syndrome: A Comprehensive Review for Dermatologists Part 2: Work-up, Diagnosis, Treatment, and Prognosis. — Journal of the American Academy of Dermatology 2026
6. AI-Assisted Line-Field Confocal Optical Coherence Tomography to Detect Subclinical Basal Cell Carcinoma. — JAMA Dermatology 2026
7. Male genital lichen sclerosus. — Journal of the European Academy of Dermatology and Venereology 2026
8. Alopecia Areata: Advances in Clinical Evaluation and Pathogenesis. — Journal of the American Academy of Dermatology 2026
9. Factors influencing quality of life in hidradenitis suppurativa: Data from 1188 patients. — Journal of the European Academy of Dermatology and Venereology 2026
10. Cardiovascular Risk Factors in Adults with Atopic Dermatitis: A Cross-sectional Study. — Acta Dermato-Venereologica 2026

Listen at AudioScholar

Welcome to This Week in Dermatology. This week we're covering 10 notable papers spanning the expanding reach of oral JAK inhibitors into vitiligo and alopecia areata, safety and risk stratification at the intersection of skin disease and cancer, and evolving standards for how we define and deliver care in atopic dermatitis and scarring. Let's dive in.

This week's papers:

1. Efficacy and safety of upadacitinib in adults and adolescents for treatment of non-segmental vitiligo (Viti-Up): results of two phase 3 randomised controlled studies. — The Lancet 2026
2. Upadacitinib for Severe Alopecia Areata in Adults and Adolescents: Two Phase 3 UP-AA Randomized Clinical Trials. — JAMA Dermatology 2026
3. Targeted therapies for psoriasis and atopic dermatitis in the context of malignancy: SPIN-FRT recommendations. — Journal of the European Academy of Dermatology and Venereology 2026
4. Alopecia areata as a sentinel condition for systemic autoimmunity: a global bidirectional cohort study. — Dermatology 2026
5. Risk Stratification Models for Cutaneous Malignant Neoplasms After Blood or Marrow Transplant. — JAMA Dermatology 2026
6. Relapse of Alopecia Areata During Ongoing JAK Inhibitor Therapy Is Not Uncommon and Usually Occurs in Previously Affected Areas: A Multicentre Italian Real-World Study. — Journal of the American Academy of Dermatology 2026
7. Real-world Effectiveness and Safety of Lebrikizumab in Atopic Dermatitis: A TREATgermany Analysis. — Acta Dermato-Venereologica 2026
8. Redefining Treat-to-target in Atopic Dermatitis: Towards Meaningful, Patient-centred Disease Control - An ISAD Position Paper. — Acta Dermato-Venereologica 2026
9. Consensus on energy-based devices for keloids and hypertrophic scars: A Latin American Delphi study. — Journal of the European Academy of Dermatology and Venereology 2026
10. Immunosuppression Outweighs Clinical AEIOU Heuristics in Predicting Disease Progression of Merkel Cell Carcinoma: A Retrospective Cohort Study. — Acta Dermato-Venereologica 2026

Listen at AudioScholar

Welcome to This Week in Dermatology. This week we're covering 10 notable papers spanning inflammatory disease classification and the economics of biologics, real-world outcomes in atopic dermatitis and psoriasis, and a cluster of practical papers on infection, hair loss, and melanocytic lesion surveillance. Let's dive in.

This week's papers:

1. Pyoderma Gangrenosum Phenotype Classification — JAMA Dermatology 2026
2. Approved Monoclonal Antibody Therapies for Hidradenitis Suppurativa — JAMA Dermatology 2026
3. Treatment of tinea capitis in China: a multicenter prospective real-world study — Journal of the American Academy of Dermatology 2026
4. Risk-adapted monitoring of melanocytic lesions with peripheral globules: a longitudinal cohort study on melanoma risk stratification — Journal of the American Academy of Dermatology 2026
5. Systemic Comorbidities in Central Centrifugal Cicatricial Alopecia: A Systematic Review and Meta-analysis — Acta Dermato-Venereologica 2026
6. Psoriatic patients with cancer: a multicentric real-life study comparing Risankizumab and Apremilast — Dermatology 2026
7. Long-term effectiveness and safety of topical finasteride 0.25% monotherapy in male androgenetic alopecia: a 52-week real-world retrospective study — Clinical and Experimental Dermatology 2026
8. Staphylococcal Scalded Skin Syndrome Often Does Not Require Empiric Coverage for Methicillin Resistance — Pediatric Dermatology 2026
9. Early Clinical Response Predicts Treatment Persistence in Advanced Therapy-naive Atopic Dermatitis — Acta Dermato-Venereologica 2026
10. Improvement of Depressive and Fatigue Symptoms under Dupilumab Therapy in Atopic Dermatitis Patients: Results from the TREATgermany Registry — Acta Dermato-Venereologica 2026

Listen at AudioScholar

Welcome to This Week in Dermatology. This week we are covering five notable papers spanning therapeutic advances and laboratory monitoring in alopecia areata, demographic variations in contact allergen sensitivities, multidimensional success metrics in hidradenitis suppurativa, and a critical update to the global naming system for biological therapies. Let's dive in.

This week's papers:

1. Clinical Yield of Laboratory Monitoring During Ritlecitinib Treatment for Alopecia Areata: A Prospective Real-World Cohort Study — Journal of the American Academy of Dermatology 2026
2. The Association of Race and Ethnicity with Patch Test Results: North American Contact Dermatitis Group Data, 2007-2020 — Journal of the American Academy of Dermatology 2026
3. Long-term Efficacy and Safety of Upadacitinib in the Treatment of Alopecia Areata: A Retrospective Study — Journal of the American Academy of Dermatology 2026
4. Measuring success in HS treatment from the physician's and the patient's perspective — Journal of the European Academy of Dermatology and Venereology 2026
5. Decoding Biological Drug Names in Dermatology: The Post-2022 WHO Nomenclature Revision and Its Implications for Clinical Practice — Journal of the American Academy of Dermatology 2026

Listen at AudioScholar

Welcome to This Week in Dermatology. This week we're covering 10 notable papers spanning systemic therapeutics for inflammatory skin disease, diagnostic imaging innovations, and pediatric and supportive care. Let's dive in.

This week's papers:

1. Povorcitinib for hidradenitis suppurativa: the randomized, double-blind, placebo-controlled STOP-HS1 and STOP-HS2 phase 3 trials. — Nature medicine 2026
2. Clinical and Dermoscopic Triage of head and neck Macules: The Role of Reflectance Confocal Microscopy in a Prospective Study of 2006 Lesions. — Journal of the American Academy of Dermatology 2026
3. Comparative effects of interventions for rosacea across phenotype-relevant outcomes: a systematic review and network meta-analysis. — Journal of the American Academy of Dermatology 2026
4. Insulin Resistance is Not a Predictor of Response to Low-Dose Oral Metformin Therapy in Patients with CCCA: A Retrospective Review. — Journal of the American Academy of Dermatology 2026
5. Magnified ultraviolet-induced fluorescence dermatoscopy for assessing mite viability in scabies. — Journal of the American Academy of Dermatology 2026
6. Initial Psychometric Validation of the Caregiver Atopic Dermatitis Control Tool. — Clinical and experimental dermatology 2026
7. High Level of Uncertainty in Assigning Causative Medications in Drug Reaction with Eosinophilia and Systemic Symptoms: A Retrospective Cohort Analysis. — Journal of the American Academy of Dermatology 2026
8. A Comprehensive Review of the Current Systemic Medical Treatment Landscape for Vascular Malformations. — Pediatric dermatology 2026
9. Durable remission with no survival reduction after mogamulizumab discontinuation in Sézary syndrome. — The British journal of dermatology 2026
10. Cutaneous leishmaniasis in patients in treatment with anti-TNF-α drugs. Study of 20 cases from a single institution. — Clinical and experimental dermatology 2026

Listen at AudioScholar

Welcome to This Week in Dermatology. This week we're covering 10 notable papers spanning systemic manifestations and novel therapeutics in psoriasis, real-world outcomes in hair restoration, and emerging safety and diagnostic data in inflammatory dermatoses. Let's dive in.

This week's papers:

1. Efficacy and safety of inhibitory magnetic stimulation in the treatment of refractory erythema of rosacea: a prospective, randomized, controlled clinical trial. — Journal of the American Academy of Dermatology 2026
2. Long-term Real-world Outcomes and Tolerability of Baricitinib in Alopecia Areata, Totalis, and Universalis: A Retrospective Single-center Cohort of 330 Patients with Trichoscopy Monitoring. — Journal of the American Academy of Dermatology 2026
3. Increased Efficacy of Daytime Low-dose Oral Minoxidil Dosing for Androgenetic Alopecia: A Retrospective Study. — The British journal of dermatology 2026
4. Cardiac structure and function in psoriasis: A cross-sectional analysis of the PSOCADIA study. — Journal of the European Academy of Dermatology and Venereology 2026
5. Malignant transformation in mucosal lichen planus: A 10-year, single-center, descriptive cohort analysis. — Journal of the American Academy of Dermatology 2026
6. Pemphigoid was not associated with increased risk of solid organ, hematologic, or nonmelanoma skin malignancies in a nationally representative matched cohort. — Clinical and experimental dermatology 2026
7. Relapse prediction in rituximab-treated pemphigus patients: A prognostic model. — Journal of the European Academy of Dermatology and Venereology 2026
8. Effect of semaglutide on hidradenitis suppurativa disease control and quality of life: A case series. — Journal of the European Academy of Dermatology and Venereology 2026
9. Missed melanoma following skin lesion triage by an autonomous artificial intelligence system in a community setting. — Clinical and experimental dermatology 2026
10. Long-term Remission of Severe Psoriasis Following CD19 CAR-T Cell Therapy for Follicular Lymphoma. — Clinical and experimental dermatology 2026

Listen at AudioScholar